Free Trial

McKesson (MCK) Stock Price, News & Analysis

$507.95
-3.67 (-0.72%)
(As of 09/19/2024 ET)

About McKesson Stock (NYSE:MCK)

Key Stats

Today's Range
$505.18
$515.43
50-Day Range
$504.17
$630.38
52-Week Range
$431.35
$637.51
Volume
862,778 shs
Average Volume
775,989 shs
Market Capitalization
$66.00 billion
P/E Ratio
22.70
Dividend Yield
0.56%
Price Target
$620.93
Consensus Rating
Moderate Buy

Company Overview

McKesson Corporation is a prominent player in the healthcare industry, offering a wide range of supply chain management solutions, retail pharmacy services, community oncology and specialty care, and healthcare information technology. With a rich history dating back to 1833, McKesson has established itself as a leading provider of essential healthcare products and services, contributing to the well-being of patients and the efficiency of healthcare providers.

The company's mission is to improve care in every setting, one product, partner, and patient at a time. McKesson operates globally, with a significant presence in the United States, Europe, and Canada, serving a diverse customer base, including hospitals, pharmacies, physician offices, surgery centers, nursing homes, and home health care agencies.

McKesson's operations are organized into several segments. The U.S. Pharmaceutical segment, one of the company's key pillars, is pivotal in distributing a comprehensive range of pharmaceutical drugs, including branded, generic, specialty, biosimilar, and over-the-counter medications. It is a crucial link in the pharmaceutical supply chain, ensuring the timely delivery of essential drugs to pharmacies and healthcare facilities across the United States.

In addition to pharmaceutical distribution, McKesson provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. The company empowers healthcare providers to optimize their practices, enhance patient care and improve overall efficiency by offering financial, operational, and clinical solutions.

McKesson's International segment extends its reach beyond the United States, providing distribution and services to wholesale, institutional, and retail customers in European countries and Canada. This global presence enables the company to leverage its expertise and resources to support healthcare systems and deliver high-quality products and services to a broader market.

The Medical-Surgical Solutions segment focuses on supply distribution, logistics, and other services. By catering to healthcare providers such as physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies, McKesson ensures that critical medical supplies are readily available, enabling efficient and effective patient care.

McKesson's management team is composed of highly experienced professionals who bring a wealth of expertise and strategic vision to the company. Led by Chief Executive Officer and Director Brian Scott Tyler, the team is dedicated to driving McKesson's mission forward. Brian Scott Tyler has been influential in steering the company toward continued growth and success. Under his leadership, McKesson has focused on innovation, strategic partnerships, and operational excellence. With a deep understanding of the healthcare landscape, Tyler has led the company through various challenges and has positioned it as a trusted partner for healthcare providers worldwide.

McKesson has consistently delivered strong financial performance, reflecting its ability to navigate the complexities of the healthcare industry while adapting to changing market dynamics. The company has demonstrated robust revenue growth over the years, driven by its diversified portfolio of products and services.

McKesson operates within the broader healthcare industry, characterized by continuous innovation, regulatory complexities, and a focus on patient care. As one of the largest healthcare distributors, McKesson faces competition from both traditional and emerging players in the market. However, the company's extensive distribution network, strong relationships with healthcare providers, and comprehensive product and service offerings give it a competitive edge.

The healthcare industry is subject to various regulatory and political factors impacting market dynamics. Changes in healthcare policies, reimbursement structures, and drug pricing regulations can significantly affect McKesson's operations. However, the company's deep industry knowledge and expertise enable it to navigate these challenges effectively.

McKesson is well-positioned to capitalize on several growth opportunities in the healthcare industry. One key area of focus is expanding its healthcare information technology solutions. As the digital transformation of the healthcare sector continues, McKesson's investments in technology and data analytics enable it to provide advanced solutions that enhance patient care, optimize workflows and drive operational efficiencies.

While McKesson has a strong market position and a track record of success, it faces certain risks and challenges that should be considered. One significant risk is the evolving regulatory landscape, including changes in healthcare policies and drug pricing regulations. Compliance with these regulations can increase costs and impact the company's profitability.

Additionally, competitive pressures within the healthcare industry require McKesson to continually innovate and differentiate its offerings. The emergence of new market entrants and disruptive technologies could challenge the company's market share and profitability.

The COVID-19 pandemic also introduced unprecedented challenges to the healthcare industry. While the pandemic presented opportunities for McKesson to support the healthcare system with essential supplies and services, it also disrupted healthcare operations and supply chains.

To mitigate these risks, McKesson has implemented robust risk management strategies. The company maintains strong relationships with regulatory bodies, stays abreast of industry trends, and invests in innovation and technology to stay ahead of the competition.

McKesson Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 100th Percentile

McKesson scored higher than 100% of companies evaluated by MarketBeat, and ranked 8th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    McKesson has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    McKesson has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about McKesson's stock forecast and price target.
  • Earnings Growth

    Earnings for McKesson are expected to grow by 10.03% in the coming year, from $32.11 to $35.33 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of McKesson is 22.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.24.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of McKesson is 22.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.17.

  • Price to Earnings Growth Ratio

    McKesson has a PEG Ratio of 1.18. PEG Ratios above 1 indicate that a company could be overvalued.

  • Read more about McKesson's valuation and earnings.
  • Percentage of Shares Shorted

    1.47% of the float of McKesson has been sold short.
  • Short Interest Ratio / Days to Cover

    McKesson has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in McKesson has recently decreased by 7.77%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    McKesson has a dividend yield of 0.56%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    McKesson has been increasing its dividend for 17 years.

  • Dividend Coverage

    The dividend payout ratio of McKesson is 12.69%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, McKesson will have a dividend payout ratio of 8.04% next year. This indicates that McKesson will be able to sustain or increase its dividend.

  • Read more about McKesson's dividend.
  • Percentage of Shares Shorted

    1.47% of the float of McKesson has been sold short.
  • Short Interest Ratio / Days to Cover

    McKesson has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in McKesson has recently decreased by 7.77%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    McKesson has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for McKesson this week, compared to 16 articles on an average week.
  • Search Interest

    Only 10 people have searched for MCK on MarketBeat in the last 30 days. This is a decrease of -66% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added McKesson to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, McKesson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,635,492.00 in company stock.

  • Percentage Held by Insiders

    Only 0.11% of the stock of McKesson is held by insiders.

  • Percentage Held by Institutions

    85.07% of the stock of McKesson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about McKesson's insider trading history.
Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

MCK Stock News Headlines

“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”
Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.
Baltimore to take drug distributors to trial over opioids
Wells Fargo & Company Cuts McKesson (NYSE:MCK) Price Target to $535.00
McKesson - Meet The New Dividend Stock On My Watchlist
See More Headlines

MCK Stock Analysis - Frequently Asked Questions

McKesson's stock was trading at $462.98 on January 1st, 2024. Since then, MCK stock has increased by 9.7% and is now trading at $507.95.
View the best growth stocks for 2024 here
.

McKesson Co. (NYSE:MCK) announced its earnings results on Wednesday, August, 7th. The company reported $7.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.21 by $0.67. The business's revenue for the quarter was up 6.4% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of McKesson: Echo, LloydsDirect, Medical Specialties Distributors, Well.ca, RxCrossroads, CoverMyMeds, HealthQx, and more.

McKesson's top institutional shareholders include Massachusetts Financial Services Co. MA (3.70%), Legal & General Group Plc (1.00%), Swedbank AB (0.92%) and Bank of New York Mellon Corp (0.78%). Insiders that own company stock include Brian S Tyler, Britt J Vitalone, Nancy Avila, Nancy Flores, Lori A Schechter, Thomas L Rodgers, Leann B Smith, Maria Martinez, Susan R Salka, Tracy Faber and Kevin Emerson.
View institutional ownership trends
.

Shares of MCK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that McKesson investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC) and AT&T (T).

Company Calendar

Ex-Dividend for 7/1 Dividend
6/03/2024
Dividend Payable
7/01/2024
Last Earnings
8/07/2024
Ex-Dividend for 10/1 Dividend
8/30/2024
Today
9/19/2024
Dividend Payable
10/01/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
CUSIP
58155Q10
Employees
51,000
Year Founded
1833

Price Target and Rating

Average Stock Price Target
$620.93
High Stock Price Target
$671.00
Low Stock Price Target
$535.00
Potential Upside/Downside
+20.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$3.00 billion
Pretax Margin
1.21%

Debt

Sales & Book Value

Annual Sales
$313.75 billion
Cash Flow
$33.05 per share
Book Value
($12.17) per share

Miscellaneous

Free Float
129,793,000
Market Cap
$66.77 billion
Optionable
Optionable
Beta
0.44

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 5, 2024. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in McKesson Co.:

  • McKesson Co. has a strong market capitalization of $71.17 billion, indicating stability and size in the market.
  • Recent insider transactions show confidence in the company, with executives purchasing shares at current levels.
  • Analysts have given McKesson Co. a consensus rating of "Moderate Buy" with a target price of $609.79, suggesting potential growth.
  • McKesson Co. has a low P/E ratio of 24.37, indicating the stock may be undervalued compared to its earnings.
  • The company has shown consistent stock performance with a 50-day moving average of $589.21, indicating a stable trend.

McKesson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in McKesson Co. for these reasons:

  • McKesson Co. has a beta of 0.45, indicating lower volatility compared to the market, potentially limiting short-term gains.
  • Recent insider selling activity has been significant, with insiders selling 32,713 shares valued at $18,702,605 in the last ninety days.
  • Stock price has been fluctuating, with a one-year high of $637.51 and a one-year low of $404.72, showing potential price volatility.
  • Some analysts have lowered their price targets on McKesson Co., indicating potential concerns about future performance.
  • The P/E/G ratio of 1.46 suggests that the stock may be overvalued relative to its expected growth rate.

This page (NYSE:MCK) was last updated on 9/19/2024 by MarketBeat.com Staff
From Our Partners